Literature DB >> 15609132

Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients.

B Tarnowski1, A Chudecka-Głaz, B Górski, I Rzepka-Górska.   

Abstract

The aim of the study was to compare VEGF serum levels in breast cancer patients with and without BRCA1 gene mutation. We enrolled 80 patients, 22 premenopausal and 58 postmenopausal. We found statistically significant lower levels of VEGF in patients with BRCA1 gene mutation as compared with breast cancer patients without this mutation.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15609132     DOI： 10.1007/s10549-004-0779-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  2 in total

1.  Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.

Authors:  Han Hsi Wong; Christine Parkinson; Jonathan A Ledermann; James D Brenton; Michael Merger; Ashley Shaw; Aileen Patterson; Mahmood Shafi; Helena M Earl
Journal:  Gynecol Oncol Case Rep       Date:  2012-10-17

2.  VEGF, HIF-1α expression and MVD as an angiogenic network in familial breast cancer.

Authors:  Concetta Saponaro; Andrea Malfettone; Girolamo Ranieri; Katia Danza; Giovanni Simone; Angelo Paradiso; Anita Mangia
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.